How to Select and Initiate At-Home tACS for Major Depressive Disorder
How can clinicians identify appropriate adults with major depressive disorder for at-home transcranial alternating current stimulation and start the treatment regimen used in this trial?
Adults with major depressive disorder often need treatment options that can be started quickly and used at home with minimal safety burden. This guide applies to the specific remote tACS approach studied in adults with moderate to severe major depressive disorder and outlines how participants were screened, qualified, and treated.
-
Confirm that the patient fits the studied population
Use this approach only for adults aged 21 to 65 years who meet DSM-5 criteria for major depressive disorder and have at least moderate depressive severity. In the trial, participants needed a Beck Depression Inventory-II score of 20 to 63 at both prescreening and baseline, and they had to have been experiencing depression for at least 1 month before treatment started.
-
Screen for exclusion criteria before proceeding
Rule out patients with a history of suicide attempt, active suicidal ideation with plan or intent in the past 30 days, psychiatric hospitalization within 1 year, neuromodulation use within 1 year, or mental health disorders other than major depressive disorder. Also exclude patients with prescription nervous system medication changes within 30 days, use of recreational substances, hypnotics, steroids, or marijuana products within 30 days, alcohol or substance abuse problems in the past 12 months, known heart disease, trigeminal neuralgia, pacemakers, or other medical electronics.
-
Use a lead-in period to confirm persistent symptoms
Before treatment, apply a 14-day lead-in period and repeat symptom assessment at baseline. In this study, the lead-in was used to reduce enrollment of patients with transient depression, and patients had to retain a BDI-II score of 20 to 63 after the lead-in to proceed.
-
Verify diagnosis with structured and clinical assessment
Review depressive symptoms with both self-report and clinician assessment rather than relying on a single questionnaire. In the trial, participants completed a self-administered Mini-International Neuropsychiatric Interview, and a study clinician then reviewed MINI responses and assessed DSM-5 criteria for major depressive disorder and other psychiatric disorders during a telemedicine interview.
-
Start the studied at-home tACS schedule
If the patient meets the same eligibility profile, the regimen studied was 20 minutes of tACS twice daily, once after waking and once before bed. The active device delivered 2 mA with a 20-minute automatic shutoff, and participants were instructed to engage in quiet activity during each treatment session.
-
Monitor daily adherence and interval outcomes
Have patients report each day whether they used the device as instructed and whether there were changes in health status or medications. In the trial, outcome and safety assessments were repeated after 1, 2, and 4 weeks, and adherence appeared clinically important because the clearest between-group benefit was seen in participants with 100% self-reported compliance during the first 14 days.
-
Track response and tolerability over the first month
Use repeated depressive symptom measures to judge early benefit, recognizing that this study used the BDI-II as the primary outcome and also collected PHQ-9 and QIDS-SR scores at follow-up. A treatment response was defined as at least 50% improvement in BDI-II score from baseline, and by week 4 the active group had a higher responder rate than sham, while no serious adverse events were reported and only 1 adverse event, skin discomfort, led to discontinuation.
Clinical Considerations
- The prespecified week 2 intent-to-treat primary end point was not statistically significant, so this protocol should not be presented as definitively superior to sham at that time point.
- The strongest efficacy signal was seen in participants with 100% self-reported adherence during the first 14 days, and adherence itself was measured by self-report.
- All depression outcomes in the trial were self-reported, which may have contributed to the high sham response and limits certainty about the magnitude of the specific device effect.
- Treatment effects beyond 4 weeks are unknown, and the sample was predominantly Caucasian, which limits generalizability.
Bottom Line
For carefully selected adults with moderate to severe major depressive disorder, the article A Fully Remote Randomized Trial of Transcranial Alternating Current Stimulation for the Acute Treatment of Major Depressive Disorder supports a pragmatic at-home tACS workflow built around strict eligibility screening, a 14-day lead-in, 20-minute twice-daily treatment, and close adherence monitoring.
